科研速递论坛-文献求助|sci-hub|谷歌学术|文献互助|文献检索|文献代理|名校资源|免费VPN|学术共享

Ulipristal

186 主题	2 好友	14 积分

炉火纯青

Rank: 4

科研币: 30
速递币: 12934
娱乐币: 833
文献值: 0
资源值: 409
贡献值: 0

发消息

电梯直达

楼主

发表于 2016-7-20 14:57:33 |只看该作者 |倒序浏览

5速递币

题名	The non-steroidal FXR agonists PX20606 and GS-9674 improve liver fibrosis and portal hypertension in rodent models of cholestatic, metabolic and toxic liver cirrhosis
链接	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0036-1583977

本帖最后由 Ulipristal 于 2016-7-20 16:07 编辑

https://www.thieme-connect.com/p ... 1055/s-0036-1583977

淘帖0 收藏0 顶0 踩0 认领应助

scofiedys

7 主题	2 好友	6 积分

渐入佳境

Rank: 3 Rank: 3

科研币: 25
速递币: 1081
娱乐币: 942
文献值: 185
资源值: 0
贡献值: 0

发消息

沙发

发表于 2016-7-20 15:21:09 |只看该作者

The non-steroidal FXR agonists PX20606 and GS-9674 improve liver fibrosis and portal hypertension in rodent models of cholestatic, metabolic and toxic liver cirrhosis
T Reiberger 1, P Schwabl 1, P Supper 1, D Bauer 1, BA Payer 1, N Rohr-Udilova 1, B Podesser 1, C Kremoser 2, M Trauner 1

1General Hospital of Vienna, Vienna, Austria
2Phenex Pharmaceuticals AG, Heidelberg, Germany

Congress Abstract

Background: FXR agonists show beneficial effects in cholestasis and NASH. We evaluated the non-steroidal FXR agonists PX20606 and GS-9674 in rodent models of toxic (CCl4), and metabolic (NASH) liver fibrosis.

Methods: Toxic model: CCl4 2x/week i.p. for 12weeks. PX20606 (10 mg/kg/day) was given from weeks4 – 12 of CCl4. NASH model: choline-deficient high-fat diet plus repeated NaNO2 (25 mg/kg i.p., 2x/week) for 10 weeks. GS-9674 (10 mg/kg/day or 30 mg/kg/day) was gavaged from weeks4 – 10, with/without propranolol (PROP, 25 mg/kg). At end of treatment, mean arterial pressure (MAP), heart rate (HR), portal pressure (PP) and superior mesenteric artery blood flow (SMABF) were measured. Liver fibrosis was assessed by Sirius Red area (SRA), content of hydroxyproline (HP). Hepatic gene expression was quantified by qRT-PCR.

Results: In CCl4 rats, PX treatment ameliorated fibrosis (SRA: 6.99 ± 3.15 vs. 3.97 ± 1.64%; p < 0.001. HP: 415 ± 86 vs. 134 ± 14 µg/g liver; p = 0.002) and decreased AST (555 ± 30 vs. 227 ± 83 IU/ml; p < 0.001) and ALT (538 ± 233 vs. 193 ± 86 IU/ml; p = 0.008). PX decreased PP (11.9 ± 1.4 vs. 9.7 ± 1.4 mmHg; p = 0.037) and increased SMABF (8.88 ± 2.62 vs. 13.81 ± 2.81 ml/min/100 g; p = 0.021), while not affecting MAP or HR. Livers of CCl4-PX rats overexpressed FXR target genes including BSEP (2.5x), SHP (2.3x) and vasodilatory mediators CSH (2.1x) and DDAH (1.7x) while vasoconstrictive endothelin-1 (0.45), PDGF-Rβ (0.51x) and αSMA (0.61x) were reduced.

GS-9674 reduced fibrosis in NASH rats in a dose-dependent manner: SRA: VEH: 9.62 ± 4.60% vs. GS-9674 – 10 mg/kg: 5.64 ± 4.51% vs. GS-9674 – 30 mg/kg: 2.94 ± 1.28%; p < 0.001). HP content was reduced by GS-9674 – 10 mg/kg: 6.40 ± 1.33 mg/L and GS-9674 – 30 mg/kg: 6.98 ± 4.74 mg/L vs. NASH-VEH: 11.89 ± 2.90 mg/L (p = 0.030). GS-9674 – 30 mg/kg decreased hepatic col1a1 (-36.5%; p = 0.030) and pdgfr-b (-36.2%; p < 0.001) whereas shp expression was increased (+159%; p < 0.01). GS-9674 decreased PP (11.9 ± 2.1 vs. 8.9 ± 2.2 mmHg; p = 0.020), the combination of GS-9674+PROP reduced SMABF (14.18 ± 3.27 to 10.48 ± 3.74mL/min/100 g; p = 0.032) while not further decreasing PP.

Conclusions: PX20606 ameliorates liver fibrosis and portal pressure in toxic cirrhosis. The novel non-steroidal FXR agonist GS-9674 exerts dose-dependent antifibrotic effects and ameliorates portal hypertension in NASH rats. The combination of GS-9674 with propranolol results in an additional decrease of mesenteric hyperperfusion.

举报该帖为应助帖

Ulipristal